Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $5.8 million.

  • Altimmune's Other Non-Current Liabilities rose 2218846.15% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 2218846.15%. This contributed to the annual value of $5.3 million for FY2024, which is 1322500.0% up from last year.
  • As of Q3 2025, Altimmune's Other Non-Current Liabilities stood at $5.8 million, which was up 2218846.15% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Other Non-Current Liabilities registered a high of $7.0 million during Q3 2021, and its lowest value of $16000.0 during Q1 2025.
  • For the 5-year period, Altimmune's Other Non-Current Liabilities averaged around $3.3 million, with its median value being $4.8 million (2021).
  • In the last 5 years, Altimmune's Other Non-Current Liabilities plummeted by 9901.48% in 2022 and then soared by 2218846.15% in 2025.
  • Over the past 5 years, Altimmune's Other Non-Current Liabilities (Quarter) stood at $6.1 million in 2021, then tumbled by 99.01% to $60000.0 in 2022, then plummeted by 33.33% to $40000.0 in 2023, then skyrocketed by 13225.0% to $5.3 million in 2024, then grew by 8.72% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $5.4 million for Q2 2025, and $16000.0 during Q1 2025.